Association Between Cannabinoid Receptor-1 Gene Polymorphism and the Risk of Diabetic Nephropathy Among Patients with Type 2 Diabetes Mellitus
Authors Zhang X, Zhu H, Xing X, Zhang C
Received 27 August 2020
Accepted for publication 6 October 2020
Published 12 November 2020 Volume 2020:13 Pages 591—599
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Martin Bluth
Xuelian Zhang,1 Haiqing Zhu,2 Xiaoyan Xing,1 Chunyu Zhang3
1Department of Endocrinology, China-Japan Friendship Hospital, Beijing 100029, People’s Republic of China; 2Department of Endocrinology, Emergency General Hospital, Beijing 100028, People’s Republic of China; 3Department of Statistical Teaching and Research, China-Japan Friendship Hospital, Beijing 100029, People’s Republic of China
Correspondence: Xiaoyan Xing
Department of Endocrinology, China-Japan Friendship Hospital, Chaoyang District, Beijing 100029, People’s Republic of China
Background: The cannabinoid receptor 1 (CNR1) gene polymorphism is reportedly associated with components of metabolic syndrome and coronary artery diseases in patients with type 2 diabetes mellitus (T2DM). We investigated whether the common variant rs10493353 polymorphism is associated with diabetic nephropathy (DN) in T2DM patients.
Patients and Methods: T2DM patients with DN were enrolled as a case group, and patients with only T2DM as a control group. Demographic data and biochemical parameters were collected. The polymerase chain reaction-based restriction fragment length polymorphism technique was used for genotyping. The odds ratio and 90% confidence interval were calculated to assess the association between genotypes and the risk of DN.
Results: In total, 320 T2DM patients and 320 DN patients were enrolled. Compared with T2DM patients, the DN patients have a significantly larger body mass index (BMI), longer duration of disease, and higher proportions of smokers, drinkers, and hypertension. The risk of DN was significantly decreased by genotypes AA (OR=0.39, 95% CI=0.23– 0.67) and GA (OR=0.53, 95% CI=0.37– 0.75) vs GG (codominant model), GA/AA vs GG (OR=0.49, 95% CI=0.35– 0.67; dominant model), AA vs GG/GA (OR=0.47, 95% CI=0.28– 0.80; recessive model), and the A allele (OR=0.52, 95% CI=0.40– 0.68; allele model). Multiple logistic regressions still show significant levels. Negative interactions were found between gene and clinical parameters, including drinking, smoking, BMI, and hypertension.
Conclusion: The A allele of CNR1 gene rs10493353 may be a protective factor for DN in T2DM patients. The risk factors of DN can affect the protective role of A allele in the progression of DN.
Keywords: diabetes mellitus, diabetic nephropathy, gene polymorphism, cannabinoid receptor 1
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]